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doi: 10.1016/j.exphThe stem cell leukemia (Scl)/Tal1 gene is essential for normal blood and endothelial develop-
ment, and is expressed in hematopoietic stem cells (HSCs), progenitors, erythroid, megakar-
yocytic, and mast cells. The Scl +19 enhancer is active in HSCs and progenitor cells,
megakaryocytes, and mast cells, but not mature erythroid cells. Here we demonstrate that
in vivo deletion of the Scl +19 enhancer (SclD19/D19) results in viable mice with normal Scl
expression in mature hematopoietic lineages. By contrast, Scl expression is reduced in the
stem/progenitor compartment and flow cytometry analysis revealed that the HSC and
megakaryocyte-erythroid progenitor populations are enlarged in SclD19/D19 mice. The
increase in HSC numbers contributed to enhanced expansion in bone marrow transplantation
assays, but did not affect multilineage repopulation or stress responses. These results affirm
that the Scl +19 enhancer plays a key role in the development of hematopoietic stem/progen-
itor cells, but is not necessary for mature hematopoietic lineages. Moreover, active histone
marks across the Scl locus were significantly reduced in SclD19/D19 fetal liver cells without
major changes in steady-state messenger RNA levels, suggesting post-transcriptional compen-
sation for loss of a regulatory element, a result that might be widely relevant given the
frequent observation of mild phenotypes after deletion of regulatory elements.  2012
ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.The stem cell leukemia (Scl) gene, also known as Tal1,
encodes a basic helix-loop-helix transcription factor that
functions as a critical regulator of both hematopoietic and
endothelial development [1]. SCL was first identified by
virtue of its ectopic expression as a target of t(1;14) chro-
mosomal translocations in T-cell acute lymphoblastic
leukemia [2]. Overexpression of SCL is now recognized
as one of the most common molecular abnormalities found
in human T-cell acute lymphoblastic leukemia [3].
Scl is an essential regulator of the hematopoietic hier-
archy at several levels. Within the hematopoietic lineage,
Scl is expressed in hematopoietic stem cells (HSCs), progen-tributed equally to this work.
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em.2012.02.006itor cells, and in erythroid, megakaryocytic, and mast cells
[4–6]. Scl null ES cells fail to differentiate in vitro and do
not contribute in vivo to hematopoiesis in chimeric mice
[6,7]. In addition, knockout of the Scl gene is embryonic
lethal at E9.5, due to complete absence of hematopoiesis
and major vascular defects [7–9]. More recently, the use of
a conditional knockout has demonstrated that Scl is essential
for the genesis, but not the maintenance, of HSCs [10,11].
Mice in which Scl was deleted in adulthood exhibited mild
defects in erythropoiesis and megakaryopoiesis [11] and
increased LincKitþScaþ stem-cell enriched population
[12]. Short-term HSC (ST-HSC) function seems to be defec-
tive in Scl deleted cells because these cells fail to generate
colony-forming unit (CFU)-S12 colonies in the spleen [10]
and show reduced short-term repopulating ability [12]. Inter-
estingly, long-term HSC (LT-HSC) function was not
compromised [11] or mildly compromised [12] when the
Scl deletion occurred post-transplantation. However, if the
deletion occurred before transplantation, then a reduction
in repopulating ability of the deleted cells was observed,
which was not due to homing defects [12]. This defect in re-
populating ability was already observed in heterozygous Sclogy and Stem Cells. Published by Elsevier Inc.
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affect the repopulation capacity of these cells [12]. Reduc-
tion of Scl expression using short hairpin RNA lentivirus
in both human and mouse stem-cell enriched populations
also affects the short and long-term repopulating ability of
these cells [13].
A systematic survey of the promoters and chromatin
structure of the murine Scl gene has identified several regu-
latory elements, functionally validated in reporter assays
[14–18]. Further analysis of reporter constructs in trans-
genic mice identified a panel of spatially distinct enhancers,
each of which directs Scl expression to a subdomain of the
normal Scl expression pattern [14,16–18]. In particular, the
Scl þ19 enhancer, also known as the Scl þ18/19 enhancer
from its location 19 kb downstream of the Scl promoter,
was shown to drive expression of Scl in long-term repopu-
lating HSCs and hematopoietic progenitors, but not in
mature cells [17,19]. Furthermore, expression of the Scl
complementary DNA under the control of the Scl þ19
enhancer rescued the formation of early hematopoietic
progenitors and yolk sac angiogenesis in Scl/ embryos,
but failed to rescue erythropoiesis and embryos still died
at E9.5 [19]. These results indicate that the Scl þ19
enhancer plays an important role in progenitors but is not
sufficient to support erythroid maturation.
Transgenic mouse reporter assays are a useful tool to iden-
tify new regulatory elements; however, such approaches are
unable to define nonredundant/essential roles of these
elements in the context of the entire gene locus. In the case
of the Scl gene, three hematopoietic enhancers have been
described that, in combination, are responsible for the hema-
topoietic expression pattern of Scl [14,16–18]. These
enhancers have evolved from common ancestral enhancers
[20] andmay havemaintained a certain degree of redundancy.
To clarify the function of the Scl þ19 enhancer within
the context of the endogenous locus, we describe here the
generation and analysis of mice lacking both copies of
the Scl þ19 enhancer (SclD19/D19). SclD19/D19 mice were
viable but their HSC and megakaryocyte-erythroid progen-
itor compartments were expanded. Analysis of Scl expres-
sion as well as chromatin modification status in wild-type
(WT) and mutant cells suggested that post-transcriptional
compensatory mechanisms contribute to the mild pheno-
type in addition to redundant regulatory elements within
the locus.Materials and methods
Mice, genotyping, and breeding
Mice with a þ18/19 targeted stem cell enhancer (SclD19/D19) were
generated as described [16]. Mice and tissues were routinely gen-
otyped by polymerase chain reaction (PCR) using the following
primers: WT allele, 50-CACCTGTCCTGGGGCTAAATT-30 and
50-GTTTTTGACTCCCAGATGTTGAA-30; þ18/19 enhancer
region deletion allele (D19), 50-CTTCTATCCATCTACAGG-30and 50-CACTGAATCATGCTCGTGTGG-30. Animals were main-
tained in the Cambridge Central Biomedical Services in accor-
dance with institutional guidelines.
Peripheral blood analysis, cell staining, and flow cytometry
A sample (50 mL) of freshly isolated peripheral blood from the tail
vein was collected and blood parameters were measured using an
ABC Vet fully automated analyzer (ABX Hematologie, Montpel-
lier, France). For hematopoietic precursor isolation, mature bone
marrow (BM) cells were depleted with a lineage depletion column
(Miltenyi Biotec, GmBH, Bergisch Gladbach, Germany). For
identification of common myeloid progenitors, granulocyte-
macrophage progenitors, and megakaryocytic erythroid progeni-
tors, cells were incubated with allophycocyanin anti-c-Kit (2B8;
Pharmingen), phycoerythrin anti-FcgRII/III (2.4G2; Pharmingen
BD Biosciences, Oxford, UK), and fluorescein isothiocyanate
(FITC) anti-CD34 (RAM34; Pharmingen). Common lymphoid
progenitors cells among Lin cells were enumerated after staining
with allophycocyanin c-Kit, Pacific Blue Sca-1 (E13-161.7; Phar-
mingen), and biotin-conjugated interleukin-7 (B12-1; Pharmin-
gen), followed by PerCP-Cy5.5 streptavidin. To further define
HSC progenitors, cells were subsequently stained with FITC
anti-CD34 antibodies. Stained cells were analyzed using a MoFlo
cell sorter (Dako, Carpinteria, CA, USA). For identification of
mast cells, a peritoneal wash was performed with 10 mL sterile
phosphate-buffered saline. Collected cells were stained with
anti–c-Kit (allophycocyanin) and anti–Sca-1 (Pacific Blue). En-
riched HSC (Lin c-Kitþ Sca-1þ) cells were sorted directly into
96% ethanol, washed extensively, and stained with propidium
iodide and anti-Ki-67 (FITC) as a marker for cell cycle analysis.
Whole BM erythropoietic cells were stained with CD71 (FITC)
and Ter119 (phycoerythrin) antibodies.
RNA isolation and quantitative PCR assays
For RNA isolation from tissues, a single-cell suspension was
prepared using a tissue homogenizer. Cells were resuspended in
TRI reagent (Sigma, St Louis, MO, USA) and RNA isolated as
described by the manufacturer. First-strand complementary DNA
synthesis was performed using the cDBA Synthesis Kit (Bioline,
Taunton, MA, USA). Quantitative PCR was carried out using Stra-
tagene Brilliant SYBR Green qPCR Master Mix (Agilent Technol-
ogies, Stockport, UK). Standard curves were obtained using serial
dilutions of control sample. Data were normalized to b-actin. Scl
messenger RNA (mRNA) primers: Scl Exon 5 F- catgttcaccaacaa-
caaccg Scl Exon 6 R ggtgtgaggaccatcagaaatctc; Scl primary
transcript primers: Scl Exon 1 F –tatgcctgtgtgcctgtgtccttt; Scl
Intron 2 R –caacactggctcccgaatacatca; b-actin primers: b-actin
F –tcctggcctcactgtcca; b-actin R –gtccgcctagaagcacttgc.
Methylcellulose colony assays
To identify progenitor colonies, single-cell suspensions of 5  104
BM or 2  105 spleen cells were plated in duplicate in semisolid
medium (MethoCult 3434; StemCell Technologies, Vancouver,
BC, Canada). Colonies were counted and identified after 7 to 10
days in culture. To detect CFU-megakaryocyte, cells were plated
in duplicate in collagen-based medium (MegaCult-C; StemCell
Technologies). After 6 to 8 days in culture, slides were dehydrated,
fixed, and stained with acetylthiocholiniodide (Sigma). Cultures
were performed according to the manufacturer’s protocol.
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Anemia was induced with phenylhydrazine (Sigma) injected intra-
peritoneally (60 mg/kg body weight) at day 1 and day 2. At day 4,
mice were analyzed.
Bone marrow transplantations
Young adult recipient mice Ly5.1 (C57/black) underwent whole
body g-irradiation with 12 Gy to ablate their BM. This was fol-
lowed immediately by tail vein injection of 1  106 (Ly5.2) cells
in a ratio of 1:1 recipient to donor WT or SclD19/D19 whole BM
cells. Animals were bled 4 and 12 weeks after BM transplantation.
All animal procedures were carried out under British Home Office
procedural and ethical guidelines.
Chromatin immunoprecipitation assay
A single-cell suspension from fetal liver isolated from E14.5
embryos was cross linked with 0.4% formaldehyde and nuclear
extracts were prepared. Nuclear extracts were sonicated to shear
the DNA and precleared with rabbit IgG (Sigma) and Protein G
agarose beads (Roche, Roche Applied Science, Burgess Hill,
UK). Specific antibodies for H3K9me3, H3K9me2, H3K4me3,
and H3K9Ac (Upstate Biotechnology, Inc., Lake Placid, NY,
USA) were added at 2.5 mg per 1  107 lysed cells and incubated
overnight at 4C. Immunoprecipitated DNA material was released
by reverse cross linking and enriched DNA fragments were puri-
fied and used for amplification by qPCR. The primers used for
the regional analysis are as described [14].
Statistical analysis
The means of each dataset were analyzed using Student’s t test
with a two-tailed distribution and assuming equal sample variance.Results
SclD19/D19 are viable and have normal mature Scl
expression in hematopoietic lineages
We have previously reported that chimeric mice created
from SclD19/D19 ES cells, where a 2.5-kb fragment contain-
ing the Scl þ18 and Scl þ19 elements was deleted, show
contribution of the deleted cells in all hematopoietic line-
ages [16]. However, in these studies, there was still WT
cell-derived hematopoiesis that might have masked quanti-
tative effects of the deletion. Therefore, to study the effects
of the deletion on hematopoiesis from embryo to adult, we
generated SclD19/D19 homozygous knockout mice by
crossing SclD19/WT heterozygous mice (Fig. 1A).
SclD19/D19 and WT mice were born at Mendelian ratios
from heterozygous crosses, demonstrating that the deletion
of the enhancer does not result in embryonic lethality.
Hematological parameters in the peripheral blood of WT
and SclD19/D19 mice were comparable at both 6 to 12 weeks
and 78 to 86 weeks of age (Table 1). Adult BM and spleen
cellularity of SclD19/D19 and WT mice were also compa-
rable (Fig. 1B). Surface marker (Ter119, Mac-1 and Gr-1,
CD41, B220, CD4, and CD8) analysis in adult BM and
spleen did not reveal any significant differences between
WT and SclD19/D19 mice (Fig. 1C). More detailed analysisof the erythroid lineage using the CD71 and Ter119
markers failed to reveal any abnormalities in erythropoiesis
in adult BM and spleen (Supplementary Figure E1A; online
only, available at www.exphem.org). In addition, phenylhy-
drazine treatment of SclD19/D19 mice induced a normal
stress erythropoiesis reaction (Supplementary Figure E1B;
online only, available at www.exphem.org).
Real-time semi-quantitative PCR performed with primers
specific for the Scl gene [16] showed that expression levels of
Scl in erythroid (Ter119þ), myeloid (Mac-1þ), megakaryo-
cytic (CD41þ), and T-cell (CD4þ) lineages were similar for
WTand SclD19/D19mice (Fig. 1D). It has recently been shown
that Scl plays a role in mast cells [21]. However, SclD19/D19
peritoneal and connective tissue mast cells were morpholog-
ically, phenotypically, and quantitatively normal (Fig. 1E and
Supplementary Figure E1C; online only, available at www.
exphem.org). To determine whether deletion of the Scl þ19
enhancer affects embryonic/fetal hematopoiesis, we quanti-
fied the number of progenitors in the fetal liver using
methylcellulose-based colony assay. No difference was
detected in burst-forming unit erythroid, CFU–granulocyte-
macrophage (GM), CFU- multipotential progenitor cells,
and CFU in culture from WT and SclD19/D19 fetuses
(Fig. 1F). The expression level of Scl was unaltered in yolk
sac at E9.5, aortagonad-mesonephros at E11.5, and fetal liver
at E11.5 and E14 (Fig. 1G).
These results indicate that deletion of the Scl þ19
enhancer results in viable mice with a normal distribution
and levels of Scl expression in embryonic and adult tissues
and no effect on BM cellularity or fetal progenitor numbers.
Scl þ19 enhancer deletion increases HSC number but
does not alter the differentiation capacity of progenitor
cells
As the Scl þ19 enhancer has been shown to be mainly
active in progenitor cells [17], we next performed a more
detailed analysis of hematopoietic progenitors. The data ob-
tained are shown in Figure 2 as a percentage of the specific
progenitor population in lineage-depleted BM. The most
significant increase in cell number (1.5-fold; p ! 0.005)
was found in the lineage-negative Sca1þ cKitþ (LSK) pop-
ulation (Fig. 2A). A similar phenotype was observed upon
Scl deletion in adult mice [12]. Further analysis of the LSK
population using the CD34 marker revealed a significant
increase in the LSK CD34þ population, whereas no differ-
ence was observed in the LSK CD34 population (Fig. 2B).
The LSK CD34þ population is enriched for ST-HSCs,
while the LSK CD34 population is enriched for the
more immature LT-HSCs [22].
A smaller but statistically significant increase of 20%
was also observed in megakaryocytic erythroid progeni-
tors, but no significant difference was observed in
granulocyte-macrophage progenitors, common myeloid
progenitors (Fig. 2C), or common lymphoid progenitors
(Fig. 2D). To complement the data, in vitro colony assays
Figure 1. SclD19/D19 mice are viable and have normal mature hematopoietic lineages. (A) Left panel shows schematic representation of the Scl alleles used in
this study: SclWT/WT and SclD19/D19 locus with the deletion of a 2.4-kb region containing both the þ18 (light green bar) and þ19 enhancers (dark green bar).
Black triangle represents loxP site remaining in the genome after Cre recombination. Scl exons are depicted in red and the Map17 exons in blue. Right panel
shows PCR genotyping analysis of WT (SclWT/WT), homozygous (SclD19/D19), and heterozygous (SclD19/WT) knockout alleles. In the first lane is 1-kb DNA
marker. (B) Analysis of total cellularity from the BM and spleen in SclWT/WT and SclD19/D19 adult mice. (C) Percentage of granulocytes (Gr1þMac1þ), mega-
karyocytes (CD41þ), and erythrocytes (Ter119þ) cells in BM and T cells (CD4þ, CD8þ) and B cells (B220þ) in spleen of SclWT/WT and SclD19/D19 mice. (D)
Scl expression in mature blood lineages of the BM and spleen in SclD19/D19 mice. Data are presented as relative expression to SclWT/WT. Erythroid cells were
sorted using Ter119 antibody, megakaryocytes using CD41, macrophages using Mac-1 and T cells from spleen using CD4. (E) Mast cells are normal in
SclD19/D19 mice. Left panel shows peritoneal cells stained with Toludine blue and Metachromatic staining of mast cells. Right panel shows quantitative anal-
ysis of mast cells (cKitþ Sca1þ) from peritoneal wash in SclWT/WT and SclD19/D19 mice.
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differentiation potential of SclD19/D19 cells (Table 2).
CFU–multipotential progenitor cells, CFU-GM, burst-
forming unit erythroid, and CFU-megakaryocyte colony
numbers were unaffected in the adult BM. By contrast,
we observed a twofold increase in CFU-GM in the spleen
of Scl knockout mice, without any sign of spleen
enlargement.The increased number of LSK cells in SclD19/D19 mice
suggested that deletion of the þ19 enhancer might play
an important role in immature HSCs. We purified CD34-
positive and negative fractions from the LSK population
and analyzed Scl expression (Fig. 2E). The level of Scl
mRNA in the LSK CD34 population was almost half
that of the WT mice (p 5 1.7  106), whereas that in
LSK CD34þ population was reduced by only 20%
Figure 1. (Continued). (F) Progenitor analysis from E11.5 fetal liver showing the number of colonies per fetal liver in WT and SclD19/D19 embryos for burst-
forming units erythroid (BFU-E), colony-forming units granulocyte-macrophage (CFU-GM), CFU multipotential (CFU-GEMM) progenitor cells, and CFU
in culture (CFU-C). (G) Quantitative analysis of Scl expression (qPCR) in intact E9 yolk sacs (YS), E11.5 aortagonad-mesonephros (AGM), and fetal liver
(FL) at E11.5 and E14 of SclWT/WT and SclD19/D19 embryos. The results are presented as relative expression to SclWT/WT.
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number of cells within the LSK population is due to cell
cycle arrest, we stained the purified LSK population for
the cell cycle marker Ki-67 (Fig. 2F). The SclD19/D19
LSK cells showed a very mild increase in G0 phase and
a slight decrease in G1 phase compared with the WT
mice; however, both changes fail to reach statistical signif-
icance. The S/G2/M phases did not differ between the two
phenotypes. This showed that the þ19 enhancer affects the
level of Scl expression in HSCs, yet the changes in HSC
numbers observed in SclD19/D19 mice are not due to major
alterations in cell cycle.
In summary, SclD19/D19 mice exhibit an increase in short-
term HSCs as assessed by flow cytometry, an increase in
megakaryocytic erythroid progenitors and an increase in
CFU-GM colonies in spleen. However, deletion of the Scl
þ19 element has no effect on the common myeloid progen-
itors, granulocyte-macrophage progenitors, and common
lymphoid progenitor populations.
The þ19 enhancer is not required for HSC multilineage
repopulation
We showed (Fig. 2A) that LSK numbers were increased by
almost twofold in SclD19/D19 mice. The ultimate assay forTable 1. Hematological parameters of SclD19/D19 and WT mice
Age (wks) Genotype N RBC (103/mL) Hgb (g/dL) Hct (%) P
6–12 WT 26 9.5 6 1.3 17.2 6 0.7 53.5 6 4.0 1
D19 26 9.6 6 1.2 16.8 6 0.8 53.1 6 3.3
78–86 WT 12 10.1 6 1.5 14.2 6 2.4 46.0 6 9.1 1
D19 13 10.6 6 1.3 14.5 6 2.1 48.3 6 8.2 1
Gran5 granulocytes; Hct5 hematocrit; Hgb5 hemoglobin; Lympho5 lymphoc
white blood cells.
Peripheral blood parameters were measured from age- and sex-matched young (HSC function is the long-term competitive repopulation
assay. A long-term competitive repopulation assay was per-
formed to assess the effect of the deletion on HSC function,
using the CD45.1–CD45.2 system to measure blood chime-
rism in transplant recipients. Donor WT or SclD19/D19 cells
were CD45.2, whereas competitor cells and recipient mice
were CD45.1 (Fig. 3A). For engraftment studies we used
a 1:1 ratio of donor to competitor and a total of 1  106 un-
fractionated donor and competitor BM cells were injected
per recipient. Results are shown in Figure 3 as a percentage
of chimerism 4 and 12 weeks post-transplantation.
Short-term engraftment was analyzed at 4 weeks post-
transplantation. Two independent transplantations were
performed and the results are shown in Figure 3B and C.
Short-term engraftment was found to be somewhat compro-
mised for SclD19/D19 cells, which is in agreement with
previous phenotypic observations in Scl conditional
knockout animals [12]. The observed reduction in engraft-
ment by the SclD19/D19 is consistent between experiments,
but fails to reach statistical significance.
Long-term engraftment was analyzed, at 12 weeks post-
transplantation. Although no significant defect was observed
with the SclD19/D19 donor cells, there was a bias for the
SclD19/D19 cells to engraft better than the WT cells (Fig. 3D).lt (103/mL) WBC (103/mL) Lympho (%) Mono (%) Gran (%)
107 6 234 7.7 6 2.0 78.7 6 5.3 4.2 6 0.5 17.1 6 5.1
965 6 209 7.4 6 2.2 78.7 6 5.7 4.3 6 1.1 17 6 4.9
551 6 254 11.3 6 7.2 64 6 13.4 6.8 6 2.4 29.2 6 11.5
527 6 353 13.7 6 5.9 64.3 6 12.1 6.8 6 1.8 29 6 10.7
ytes; mono5 monocytes; Plt5 platelets; RBC5 red blood cells; WBC5
6–12 weeks) and old (78–86 weeks) mice.
Figure 2. Phenotypic analysis of progenitor cells in adult BM of WT and SclD19/D19 mice. (A) SclD19/D19 animals have an increased number of LinSca1þKitþ
cells compared with the SclWT/WT. Histogram shows percentage of Sca1þKitþ cells within the Lin BM cells of SclWT/WT and SclD19/D19 mice. (B) No signif-
icant difference is observed in the number of long-term CD34 stem cells in the two genotypes; however, there is a 2-fold increase in short-term CD34þ stem
cells in SclD19/D19 mice. Histogram show percentage of CD34þ and CD34 within the LSK population in BM. (C) Analysis of BM progenitor population
reveals a normal population of granulocyte-macrophage progenitors (GMPs) and common myeloid progenitors but an increase in the megakaryocytic erythroid
progenitor (MEP) population in SclD19/D19. (D) No difference was observed in the number of common lymphoid progenitors (CLPs) between WTand SclD19/D19
animals. (E) Expression level of Scl in short-term (LSK CD34þ) and long-term (LSK CD34) stem cells. (F) Cell cycle fluorescence-activated cell sorting
analysis on sorted LSK population stained for the Ki-67 and propidium iodide (PI) in SclWT/WT and SclD19/D19 mice. Left panel shows representative plots
and right panel shows quantification results. Analysis was performed on six animals from each genotype.
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Table 2. Hematopoietic progenitors are normal in SclD19/D19 mice
Tissue Genotype BFU-e CFU-GM CFU-GEMM CFU-MK
BM WT 2 6 1 28 6 16 4 6 2 13 6 4
D19 2 6 1 26 6 12 3 6 3 15 6 1
Spleen WT 3 6 1 17 6 2 5 6 2 9 6 6
D19 4 6 1 34 6 6 5 6 2 11 6 9
Methylcellulose-based colony assays where performed in whole BM and
spleen from WT and D19 mice. The numbers shown are per 5  104
BM and 2  105 spleen cells for burst-forming units-erythroid (BFU-e),
colony-forming units–granulocyte macrophage (CFU-GM), CFU–multipo-
tential progenitors (CFU-GEMM), and CFU- megakaryocytes (CFU-MK).
Results represent six age- and sex-matched mice of each genotype. Values
are expressed as mean 6 standard deviation.
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calculated (Fig. 3E), we did not observe any significant differ-
ences for any lineage engraftment contribution.Redundancy of the Scl regulatory elements
We previously identified several different regulatory elements
that control the spatial and temporal expression of the Scl gene
in vitro and in vivo [16,17,23], which are summarized in
Figure 4A. The Scl þ19 element is controlled by a multipro-
tein complex that includes GATA-2, Fli-1, and Elf-1 [16]. To
identify possible redundancy between the þ19 enhancer and
other Scl regulatory elements, we performed chromatin
immunoprecipitation (ChIP) assays on E14.5 fetal liver cells
with markers for repressive (H3K9me3 and H3K9me2) and
active (H3K4me3 and H3K9Ac) chromatin. Using the two
markers for repressive chromatin, we did not observe any
differences between the SclD19/D19 and SclWT/WT fetal liver
cells at different elements of the Scl locus (Fig. 4B, bottom
panels). By contrast, ChIP performedwith active euchromatin
marks revealed changes at Scl promoter region 1b (Fig. 4B,
top panels). Interestingly, both active euchromatin marks are
reduced in SclD19/D19 fetal liver cells, indicating that the
Scl þ19 element is required for enhanced activity of the Scl
promoter. Another region that was significantly decreased
by the Scl þ19 deletion was the Scl-4 enhancer located 4 kb
upstream of the start site of the Scl coding sequence. Chro-
matin analysis of the endogenous gene locus therefore demon-
strates direct functional consequences of the deletion of
a distal enhancer on the status of the Scl promoter region.
Surprisingly, the expression of Scl mRNA is unaltered in
SclD19/D19 E14.5 fetal livers (Fig. 1G and Fig. 4C), suggest-
ing post-transcriptional compensation. To test this hypoth-
esis, we quantified the amount of Scl primary transcript
present in WT and mutant fetal liver cells from the same
litters by qPCR using primers spanning the exon 1b:intron1
boundary (Fig. 4C). This analysis demonstrated a 50%
reduction of primary transcript in mutant cells, consistent
with the ChIP data over the Scl promoter 1B. Taken
together therefore, our results reveal post-transcriptional
compensatory mechanisms as the likely cause for thesimilar levels of steady-state mRNA in wild type and
enhancer-deleted cells.Discussion
The murine Scl locus has emerged, over the past decade or
so, as a paradigm gene locus for studying transcriptional
control mechanisms in blood stem and progenitor cells
[14–18,20,23–25]. Concerted biochemical, comparative
genomics, and transgenic studies led to the identification
of three distinct regions (4, þ19, and þ40) active in
progenitor cells, with the þ19 enhancer being the most
specific HSC enhancer element [14,16,17,19,23]. Impor-
tantly, none of the previous studies of Scl regulation had
performed extensive analysis of steady-state hematopoiesis
after deletion of regulatory elements from the endogenous
locus. Here we report a comprehensive phenotypic analysis
of mice lacking the Scl þ19 enhancer. SclD19/D19 are viable
with specific defects in the hematopoietic stem/progenitor
cell compartment. However, SclD19/D19 HSCs did not
display any significant imbalance in the production of
mature cells, and were able to function in transplantation
assay. Rather than being accompanied by compensatory
increases in active chromatin marks elsewhere in the locus,
deletion of the þ19 enhancer causes a reduction of active
histone marks at the 4 enhancer and Scl promoters.
The observation of relatively mild phenotypes after the
deletion of regulatory elements is a common finding. Early
studies on b-globin enhancers showed only moderate
reductions in expression [26–28] and similar results were
also obtained after the deletion of the a-globin upstream
enhancer [29]. Perhaps the most publicized failure to elicit
strong phenotypes after deletion of enhancer elements
comes with the demonstration that germline deletion of
four ultra-conserved elements did not cause any major
phenotype [30]. Given that the complete knockout of genes
such as Scl or globins results in major phenotypes, the
minor phenotypes after enhancer knockouts have
commonly been attributed to compensation by additional
regulatory elements with overlapping activity, within the
same gene locus. Most recently, Snow and colleagues
[31] have shown that deletion of a Gata2 enhancer, pre-
dicted to be responsible for the Gata2-dependent positive
feedback loop in HSCs, had no major phenotypical conse-
quences despite a significant reduction in Gata2 expression
and the lack of phenotype was again attributed to redun-
dancy with another cis-regulatory element.
We have previously demonstrated that the Scl þ19
element is controlled by amultiprotein complex that includes
GATA-2, Fli-1, and Elf-1 [16]. Using whole-genome tran-
scription factor binding mapping by ChIP-Seq, we have
recently identified other important hematopoietic regulators
that also bind to the Scl þ19 enhancer, including the Ets
factors Pu.1 and Erg [32,33]. Like GATA-2 and Fli1, Pu.1
and Erg were also bound to other Scl enhancers (4 and/or
Figure 3. Enhanced long-term repopulation in SclD19/D19 mice. (A) Outline of transplantation assay. CD45.2 SclWT/WT or SclD19/D19 unfractionated BM
was mixed with CD45.1 unfractionated BM at a ratio of 1:1. Five to six lethally irradiated CD45.1 recipients were injected with 1  106 cells per group
(SclD19/D19 or SclWT/WT donor CD45.2). (B) Percentage reconstitution (CD45.2þ cells) measured 4 weeks post-transplantation by fluorescence-activated
cell sorting (FACS) analysis of peripheral blood with CD45.1 and CD45.2 antibodies. (C) Recipient peripheral blood FACS analysis for different lineage
markers: B cells (B220), macrophages (Mac-1), and T cells (CD4). CD45.2 donor reconstitution for each lineage is expressed as a percentage. (D)
Percentage reconstitution measured 12 weeks post-transplantation by FACS analysis of peripheral blood with CD45.1 and CD45.2 antibodies. Two inde-
pendent transplantations are shown. (E) Recipient peripheral blood FACS analysis for different lineage markers: B cells (B220), macrophages (Mac-1),
and T cells (CD4). CD45.2 donor reconstitution for each lineage is expressed as a percentage.
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Figure 4. Decreased activity at Scl promoters in SclD19/D19 mice. (A) The mouse Scl and neighboringMap17 gene loci. Scl exons are depicted in red and the
Map17 exons in blue. Arrows indicate functionally characterized Scl regulatory elements. The number above each arrow indicates the position, in kb, of the
enhancer in relation to the Scl promoter 1a. 1a- Scl Promoter 1a; 1b- Scl Promoter 1b. (B) ChIP assay for active (H3K4me3 and H3K9Ac) and repressive
(H3K9me3 and H3K9me2) chromatin marks. Fold enrichment was compared with that of the IgG control. (C) qRT-PCR analysis of Scl primary transcript
and mRNA expression in E14.5 fetal liver cells shows a reduction of primary transcript levels in enhancer deleted cells.
596 D. Spensberger et al./ Experimental Hematology 2012;40:588–598þ40 regions), suggesting that the entire Scl transcriptional
domain serves as a target for these upstream regulators. Of
note, the recurrent presence of overlapping sets of transcrip-
tion factors at several enhancers of a particular gene locusmay be one of the reasons that deletion of individual enhancer
elements often causes only mild phenotypes.
HSCs have the ability of self-renewal, extensive prolifer-
ation, and to contribute to all lineages of hematopoiesis.
597D. Spensberger et al./ Experimental Hematology 2012;40:588–598Adult HSCs can be divided into LT-HSC and ST-HSC pop-
ulations. We observed a significant increase in the HSC-
enriched LSK population in SclD19/D19 mice. Of note,
a similar phenotype has been described previously using
conditional deletion of Scl in adult HSCs [12], demon-
strating the specific function of the þ19 element in HSC
expression of Scl. Furthermore, even though the ST-HSCs
and LT-HSCs in our SclD19/D19 mouse model showed
a reduced level of Scl expression, there was no major defect
in the long-term competitive repopulation assay, which
again is consistent with analysis of adult HSC function in
conditional Scl knockout mice [10–12]. However, unlike
the conditional Scl knockout, the SclD19/D19 mutation is
constitutive and, therefore, present at the early develop-
mental stages where Scl function is absolutely critical [6–
8]. Importantly, the data presented here suggests that the
main compensatory mechanism for loss of the Scl þ19
enhancer may not be through alternative regulatory
elements. This notion is based on the observation that,
despite the lack of change in steady-state mRNA levels,
active histone marks over the Scl promoter as well as the
levels of Scl primary transcripts were reduced significantly
after deletion of the þ19 enhancer from the endogenous Scl
locus. It has been shown previously that Scl mRNA stability
is enhanced during terminal erythroid maturation [34], thus
providing a potential mechanism for post-transcriptional
control of Scl mRNA steady-state levels.
It is, of course, not unexpected that the activity of impor-
tant regulators such as Scl is controlled at multiple levels
from transcription [14–19,23,24,35] to post-transcriptional
[34,36] to translational [37] to post-translational [38]
control. Compensation for loss of a transcriptional regula-
tory element can occur at any of those levels. The studies
reported here have therefore not only demonstrated
a remarkable tissue-specific function for the Scl þ19
stem cell enhancer, but also highlight the need to consider
nontranscriptional compensatory mechanisms when inter-
preting enhancer knockout phenotypes.Acknowledgments
We are grateful to Tina Hamilton and Dean Pask for animal
husbandry. Work in the authors’ laboratories is funded by grants
from the Wellcome Trust, Leukaemia and Lymphoma Research,
Leukemia & Lymphoma Society, MRC, BBSRC, CRUK and
National Institute for Health Research Biomedical Research
Centre.
Conflict of interest disclosure
No financial interest/relationships with financial interest relating
to the topic of this article have been declared.
References
1. Bloor AJ, Sanchez MJ, Green AR, Gottgens B. The role of the
stem cell leukemia (SCL) gene in hematopoietic and endotheliallineage specification. J Hematother Stem Cell Res. 2002;11:195–
206.
2. Begley CG, Aplan PD, Davey MP, et al. Chromosomal translocation in
a human leukemic stem-cell line disrupts the T-cell antigen receptor
delta-chain diversity region and results in a previously unreported
fusion transcript. Proc Natl Acad Sci U S A. 1989;86:2031–2035.
3. Begley CG, Green AR. The SCL gene: from case report to critical
hematopoietic regulator. Blood. 1999;93:2760–2770.
4. Elefanty AG, Begley CG, Metcalf D, Barnett L, Kontgen F, Robb L.
Characterization of hematopoietic progenitor cells that express the
transcription factor SCL, using a lacZ ‘‘knock-in’’ strategy. Proc
Natl Acad Sci U S A. 1998;95:11897–11902.
5. Elefanty AG, Begley CG, Hartley L, Papaevangeliou B, Robb L. SCL
expression in the mouse embryo detected with a targeted lacZ reporter
gene demonstrates its localization to hematopoietic, vascular, and
neural tissues. Blood. 1999;94:3754–3763.
6. Robb L, Elwood NJ, Elefanty AG, et al. The scl gene product is
required for the generation of all hematopoietic lineages in the adult
mouse. EMBO J. 1996;15:4123–4129.
7. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The
T cell leukemia oncoprotein SCL/tal-1 is essential for development of
all hematopoietic lineages. Cell. 1996;86:47–57.
8. Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis
from mice with a targeted disruption of the scl gene. Proc Natl
Acad Sci U S A. 1995;92:7075–7079.
9. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in
mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature.
1995;373:432–434.
10. Hall MA, Curtis DJ, Metcalf D, et al. The critical regulator of embry-
onic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis,
erythropoiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci
U S A. 2003;100:992–997.
11. Mikkola HK, Klintman J, Yang H, et al. Haematopoietic stem cells
retain long-term repopulating activity and multipotency in the absence
of stem-cell leukaemia SCL/tal-1 gene. Nature. 2003;421:547–551.
12. Curtis DJ, Hall MA, Van Stekelenburg LJ, Robb L, Jane SM, Begley
CG. SCL is required for normal function of short-term repopulating
hematopoietic stem cells. Blood. 2004;103:3342–3348.
13. Brunet de la Grange P, Armstrong F, Duval V, et al. Low SCL/TAL1
expression reveals its major role in adult hematopoietic myeloid
progenitors and stem cells. Blood. 2006;108:2998–3004.
14. Delabesse E, Ogilvy S, Chapman MA, Piltz SG, Gottgens B, Green
AR. Transcriptional regulation of the SCL locus: identification of an
enhancer that targets the primitive erythroid lineage in vivo. Mol
Cell Biol. 2005;25:5215–5225.
15. Gottgens B, Barton LM, Gilbert JG, et al. Analysis of vertebrate SCL
loci identifies conserved enhancers. Nat Biotechnol. 2000;18:181–186.
16. Gottgens B, Broccardo C, Sanchez MJ, et al. The scl þ18/19 stem cell
enhancer is not required for hematopoiesis: identification of a 5’
bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and
Elf-1. Mol Cell Biol. 2004;24:1870–1883.
17. Sanchez M, Gottgens B, Sinclair AM, et al. An SCL 3’ enhancer
targets developing endothelium together with embryonic and adult
haematopoietic progenitors. Development. 1999;126:3891–3904.
18. Sinclair AM, Gottgens B, Barton LM, et al. Distinct 5’ SCL enhancers
direct transcription to developing brain, spinal cord, and endothelium:
neural expression is mediated by GATA factor binding sites. Dev Biol.
1999;209:128–142.
19. Sanchez MJ, Bockamp EO, Miller J, Gambardella L, Green AR.
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice
by expressing Scl under the control of a stem cell enhancer. Develop-
ment. 2001;128:4815–4827.
20. Gottgens B, Ferreira R, Sanchez MJ, et al. cis-Regulatory remodeling
of the SCL locus during vertebrate evolution. Mol Cell Biol. 2010;30:
5741–5751.
598 D. Spensberger et al./ Experimental Hematology 2012;40:588–59821. Salmon JM, Slater NJ, Hall MA, et al. Aberrant mast-cell differentia-
tion in mice lacking the stem-cell leukemia gene. Blood. 2007;110:
3573–3581.
22. Yang L, Bryder D, Adolfsson J, et al. Identification of Lin(-)Sca1(þ)
kit(þ)CD34(þ)Flt3- short-term hematopoietic stem cells capable of
rapidly reconstituting and rescuing myeloablated transplant recipients.
Blood. 2005;105:2717–2723.
23. Ogilvy S, Ferreira R, Piltz SG, Bowen JM, Gottgens B, Green AR.
The SCL þ40 enhancer targets the midbrain together with primitive
and definitive hematopoiesis and is regulated by SCL and GATA
proteins. Mol Cell Biol. 2007;27:7206–7219.
24. Gottgens B, Nastos A, Kinston S, et al. Establishing the transcriptional
programme for blood: the SCL stem cell enhancer is regulated by
a multiprotein complex containing Ets and GATA factors. EMBO J.
2002;21:3039–3050.
25. Silberstein L, Sanchez MJ, Socolovsky M, et al. Transgenic analysis of
the stem cell leukemia þ19 stem cell enhancer in adult and embryonic
hematopoietic and endothelial cells. Stem Cells. 2005;23:1378–1388.
26. Bender MA, Byron R, Ragoczy T, Telling A, Bulger M, Groudine M.
Flanking HS-62.5 and 3’ HS1, and regions upstream of the LCR, are
not required for beta-globin transcription. Blood. 2006;108:1395–1401.
27. Bender MA, Roach JN, Halow J, et al. Targeted deletion of 5’HS1 and
5’HS4 of the beta-globin locus control region reveals additive activity
of the DNaseI hypersensitive sites. Blood. 2001;98:2022–2027.
28. Hug BA, Wesselschmidt RL, Fiering S, et al. Analysis of mice con-
taining a targeted deletion of beta-globin locus control region 5’
hypersensitive site 3. Mol Cell Biol. 1996;16:2906–2912.
29. Anguita E, Sharpe JA, Sloane-Stanley JA, Tufarelli C, Higgs DR,
Wood WG. Deletion of the mouse alpha-globin regulatory element(HS -26) has an unexpectedly mild phenotype. Blood. 2002;100:
3450–3456.
30. Ahituv N, Zhu Y, Visel A, et al. Deletion of ultraconserved elements
yields viable mice. PLoS Biol. 2007;5:e234.
31. Snow JW, Trowbridge JJ, Johnson KD, et al. Context-dependent func-
tion of ‘‘GATA switch’’ sites in vivo. Blood. 2011;117:4769–4772.
32. Tijssen MR, Cvejic A, Joshi A, et al. Genome-wide analysis of
simultaneous GATA1/2, RUNX1, FLI1, and SCL binding in mega-
karyocytes identifies hematopoietic regulators. Dev Cell. 2011;20:
597–609.
33. Wilson NK, Foster SD, Wang X, et al. Combinatorial transcriptional
control in blood stem/progenitor cells: genome-wide analysis of ten
major transcriptional regulators. Cell Stem Cell. 2010;7:532–544.
34. Murrell AM, Bockamp EO, Gottgens B, et al. Discordant regulation of
SCL/TAL-1 mRNA and protein during erythroid differentiation.
Oncogene. 1995;11:131–139.
35. Bockamp EO, McLaughlin F, Murrell AM, et al. Lineage-restricted
regulation of the murine SCL/TAL-1 promoter. Blood. 1995;86:
1502–1514.
36. Begley CG. The SCL transcription factor and differential regulation of
macrophage differentiation by LIF, OSM and IL-6. Stem Cells. 1994;
12(suppl 1):143–149. discussion 149–151.
37. Calkhoven CF, Muller C, Martin R, et al. Translational control of
SCL-isoform expression in hematopoietic lineage choice. Genes
Dev. 2003;17:959–964.
38. Tang T, Arbiser JL, Brandt SJ. Phosphorylation by mitogen-activated
protein kinase mediates the hypoxia-induced turnover of the
TAL1/SCL transcription factor in endothelial cells. J Biol Chem.
2002;277:18365–18372.
Supplementary Figure E1. SclD19/D19 mice hematopoietic phenotype. (A) Representative fluorescence-activated cell sorting analysis of CD71 and Ter119
staining of adult BM shows a normal erythroid differentiation profile for WT and SclD19/D19 mice. (B) Erythropoiesis of 6- to 8-week-old sex- and age-
matched SclWT/WT and SclD19/D19 mice was stressed with phenylhydrazine (PHZ). Burst-forming erythriod (BFU-e) colonies were increased equally in
the spleens of SclWT/WT and SclD19/D19 mice 4 days after the first injection. (C) Left panel shows representative ear sections of SclWT/WT and SclD19/D19
stained with Toluidine blue and quantification of mast cells is summarized in histogram.
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